专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2013097022A2 PROTEÍNAS RECOMBINANTES, POLINUCLEOTÍDEOS E VACINAS CONTRA HERPESVÍRUS BOVINOS 审中-公开
标题翻译：重组蛋白，多核苷酸和疫苗对牛疱疹病毒
公开(公告)号：WO2013097022A2
公开(公告)日：2013-07-04
申请号：PCT/BR2013/000006
申请日：2013-01-02
申请人： UNIVERSIDADE FEDERAL DE MINAS GERAIS - UFMG , FIGUEIREDO BARBOSA STANCIOLI, Edel , GUIMARÃES DA FONSECA, Flavio , LAGUARDIA NASCIMENTO, Mateus , BORGES FERRARI, Amanda , SILVA BARBOSA, Aline Aparecida
发明人： FIGUEIREDO BARBOSA STANCIOLI, Edel , GUIMARÃES DA FONSECA, Flavio , LAGUARDIA NASCIMENTO, Mateus , BORGES FERRARI, Amanda , SILVA BARBOSA, Aline Aparecida
IPC分类号： C07K14/035
CPC分类号： A61K39/265 , A61K39/12 , A61K2039/552 , A61K2039/70 , C07K14/005 , C12N2710/16722 , C12N2710/16734 , C12N2799/023
摘要： A presente tecnologia descreve a produção de uma vacina contendo proteínas recombinantes compreendendo 04 epitopos das principais proteínas antigênicas de cada um de dois herpesvírus bovinos, BoHV-1 ( Bovine herpesvirus 1) e BoHV-5 ( Bovine herpesvirus 5), produzidas em sistema procarioto e/ou em sistema eucarioto utilizando vírus recombinante gerado na plataforma MVA (Vírus Ankara Modificado). Especificamente, cada proteína recombinante contém 04 epitopos produzidos de forma linear, uma com os epitopos de BoHV-1 e a outra com os epitopos de BoHV-5, e os epitopos ligados com o uso de alças flexíveis de glicina e serina para unir as regiões desejadas e permitir a conformação terciária adequada de cada fragmento, resultando em duas proteínas multiepitopo que têm o potencial de imunizar ruminantes (especialmente bovinos) contra os virus BoHV-1 e BoHV-5 para o controle da infecção, disseminação virai e redução do prejuízo económico causado por duas doenças bovinas de grande importância para o setor pecuário mundial: Rinotraqueíte Infecciosa bovina e Encefalite bovina.
摘要翻译：
此技术描述了生产MAKE-HANDS中，包含蛋白质＆iacute疫苗;在重组包含的主要蛋白质＆iacute的04抗原决定簇;在古＆ecirc; niques每两个herpesv＆iacute的; RUS牛，牛疱疹病毒1型（牛疱疹病毒 1），牛疱疹病毒5型（牛疱疹病毒 5），在原核系统和/或真核生物系统产生使用v＆iacute;在MVA平台产生重组RUS（v＆iacute Mod安卡拉）。具体地，每个蛋白iacute;在含有重组＆eacute; M 04表位线性产生一个与牛疱疹病毒的表位的1型和其他与牛疱疹病毒5型的与使用的Al MAKE-FLEX＆iacute相关的表位，和表位; BATCH 甘氨酸和丝氨酸为接合区域＆otilde;期望的ES，并允许符合MAKE-手中，Terci合适的RIA各片段，得到两种蛋白质＆iacute;在具有multiepitopo＆ecirc;莫潜在免疫反刍动物（特别是牛）抗病毒BoHV -1和BoHV-5用于控制感染，病毒传播和减少对该部门非常重要的两种牛疾病造成的经济损害世界牛：牛感染性鼻气管炎和牛脑炎。

2. 发明申请

WO2012106377A2 NUCLEIC ACID MOLECULES ENCODING NOVEL HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USE THEREOF 审中-公开
标题翻译：编码新型抗原的核酸分子，包含其的疫苗及其使用方法
公开(公告)号：WO2012106377A2
公开(公告)日：2012-08-09
申请号：PCT/US2012/023398
申请日：2012-01-31
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA , WEINER, David B , SHEDLOCK, Devon J
发明人： WEINER, David B , SHEDLOCK, Devon J
IPC分类号： A61K48/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/245 , A61K39/25 , A61K2039/53 , C12N7/00 , C12N2710/16011 , C12N2710/16111 , C12N2710/16122 , C12N2710/16134 , C12N2710/16622 , C12N2710/16634 , C12N2710/16722 , C12N2710/16734
摘要： Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against herpes virus using the vaccines that are provided.
摘要翻译：本文提供了编码疱疹病毒抗原的新的共有氨基酸序列的核酸序列，以及表达序列的遗传构建体/载体和疫苗。本文还提供了使用所提供的疫苗产生针对疱疹病毒的免疫应答的方法。

3. 发明申请

WO2012051211A3 ANTIGEN DELIVERY PLATFORMS 审中-公开
标题翻译：抗原递送平台
公开(公告)号：WO2012051211A3
公开(公告)日：2012-06-07
申请号：PCT/US2011055834
申请日：2011-10-11
申请人： NOVARTIS AG , LILJA ANDERS , LOOMIS REBECCA , FRANTI MICHAEL , MASON PETER
发明人： LILJA ANDERS , LOOMIS REBECCA , FRANTI MICHAEL , MASON PETER
IPC分类号： A61K39/12 , C07K14/005 , C12N15/86
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/55555 , C07K2319/92 , C12N15/86 , C12N2710/16122 , C12N2710/16134 , C12N2710/16722 , C12N2710/16734 , C12N2770/36143 , C12N2830/20 , C12N2840/203
摘要： This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.
摘要翻译：本公开提供了将疱疹病毒蛋白递送至细胞的平台，特别是在体内形成复合物的蛋白质。在一些实施方案中，这些蛋白质及其形成的复合物引起有效的中和抗体。因此，使用所公开的平台表达疱疹病毒蛋白质可以产生用于疫苗开发的广泛和有效的免疫反应。

4. 发明申请

WO2011011971A1 ORF7缺陷型水痘病毒、含有该病毒的疫苗及应用审中-公开
公开(公告)号：WO2011011971A1
公开(公告)日：2011-02-03
申请号：PCT/CN2010/001139
申请日：2010-07-27
申请人：新泽西医学院 , 北京万泰生物药业股份有限公司 , 厦门大学 , 朱桦 , 李益民 , 夏宁邵 , 程通 , 叶祥忠
发明人：朱桦 , 李益民 , 夏宁邵 , 程通 , 叶祥忠
IPC分类号： C12N7/00 , C12N7/04 , C12N7/01 , A61K39/25 , A61P31/22 , C12N15/63 , C12N5/10
CPC分类号： C12N7/00 , A61K39/12 , A61K39/25 , A61K2039/5254 , C07K14/005 , C12N15/86 , C12N2710/16722 , C12N2710/16734

5. 发明申请

WO2006094756A3 VARICELLA ZOSTER VIRUS VACCINE 审中-公开
公开(公告)号：WO2006094756A3
公开(公告)日：2007-02-15
申请号：PCT/EP2006002070
申请日：2006-03-01
申请人： GLAXOSMITHKLINE BIOLOG SA , HANON EMMANUEL JULES , STEPHENNE JEAN
发明人： HANON EMMANUEL JULES , STEPHENNE JEAN
IPC分类号： C07K14/04 , A61K39/00 , A61K39/25 , A61K39/39 , A61P31/22 , C12N7/04
CPC分类号： A61K39/25 , A61K39/00 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , C07K14/005 , C12N2710/16722 , C12N2710/16734
摘要： Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed.
摘要翻译：包含VZV gE或其免疫原性片段和TH-1佐剂的免疫原性组合物在制备用于预防或改善带状疱疹和/或疱疹后神经痛的药物中的用途。还要求包含截短的VZV gE抗原和含有QS21，胆固醇和3D MPL的佐剂的组合物。

6. 发明申请

WO2004042031A3 SAFER ATTENUATED VIRUS VACCINES WITH MISSING OR DIMINISHED LATENCY OF INFECTION 审中-公开
标题翻译：安全的病毒疫苗缺失或感染时间延长
公开(公告)号：WO2004042031A3
公开(公告)日：2004-09-16
申请号：PCT/US0335167
申请日：2003-11-05
申请人： US GOV HEALTH & HUMAN SERV , COHEN JEFFREY IRVINE , COX EDWARD MICHAEL , PESNICAK LESLEY M
发明人： COHEN JEFFREY IRVINE , COX EDWARD MICHAEL , PESNICAK LESLEY M
IPC分类号： C07K14/03 , C07K14/035 , C07K14/04 , C07K14/055 , C12N7/04 , C12N7/00 , A61K39/245 , C12N5/00
CPC分类号： C12N7/00 , A61K2039/5254 , C07K14/005 , C12N2710/16322 , C12N2710/16622 , C12N2710/16722 , C12N2710/16761
摘要： Viruses having weakened ability to establish and/or maintain latency and their use as live vaccines are described. The vaccines have one or more alterations in genes that provide continued virus replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the varicella zoster virus. Deletion of a significant portion from both copies of the varicella zoster gene ORF63 was shown to inhibit establishment of a latent infection from a live vaccine form of the virus. Other desirable viral antigen encoding sequence(s) and/or cytokine genes advantageously may replace deleted genetic material to enhance a desired immunological response. Aspects of the discovery pertain to live vaccines of other viruses, and can provide a variety of vaccines having greater safety.
摘要翻译：描述了具有削弱建立和/或维持延迟的能力及其作为活疫苗的用途的病毒。疫苗在提供持续病毒复制但抑制潜伏期的基因中具有一个或多个改变。用于其构建的疫苗材料和方法以水痘带状疱疹病毒为例。从水痘带状疱疹基因ORF63的两个拷贝中删除重要部分被证明可以抑制病毒活疫苗形式的潜伏感染的建立。其他所需的病毒抗原编码序列和/或细胞因子基因有利地可以代替缺失的遗传物质以增强所需的免疫应答。该发现的方面涉及其他病毒的活疫苗，并且可以提供具有更高安全性的多种疫苗。

7. 发明申请

WO0166568A3 USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL 审中-公开
标题翻译：使用重组抗原来确定动物的免疫状态
公开(公告)号：WO0166568A3
公开(公告)日：2003-01-23
申请号：PCT/US0107251
申请日：2001-03-07
申请人： HESKA CORP , UNIV COLORADO STATE RES FOUND , JENSEN WAYNE A , LAPPIN MICHAEL R , ROSEN DAVID K , ANDREWS JANET S
发明人： JENSEN WAYNE A , LAPPIN MICHAEL R , ROSEN DAVID K , ANDREWS JANET S
IPC分类号： C07K14/005 , C07K14/015 , C07K14/03 , C07K14/08 , C07K14/13 , C07K14/15 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/02 , G01N33/53 , G01N33/536 , G01N33/569
CPC分类号： C07K14/005 , C12N2710/16722 , C12N2740/13022 , C12N2750/14322 , C12N2750/14343 , C12N2760/18422 , G01N33/56983
摘要： The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation of a complex between the recombinant antigen and the antibody and (b) detecting the presence or absence of the complex, wherein presence or absence of a complex is indicative of the immune status of the animal. Preferably such a method indicates whether the animal should be vaccinated. The present invention also includes an assay comprising (a) a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent; and (b) a means to detect an antibody that selectively binds to the recombinant antigen. Also included in the present invention are recombinant antigens and nucleic acid molecules encoding such antigens as well as methods to produce and use such nucleic acid molecule and recombinant antigens.
摘要翻译：本发明包括确定动物的免疫状态的方法，其包括以下步骤：（a）在条件下使动物的生物标本与特异于检测针对该感染因子的抗体的重组感染原体抗原接触适合于在重组抗原和抗体之间形成复合物，和（b）检测复合物的存在或不存在，其中复合物的存在或不存在指示动物的免疫状态。优选地，这种方法指示动物是否应该接种疫苗。本发明还包括一种测定法，其包含（a）特异于检测针对该感染因子的抗体的抗体的重组感染原体抗原; 和（b）检测选择性结合重组抗原的抗体的方法。本发明还包括编码这种抗原的重组抗原和核酸分子以及产生和使用这种核酸分子和重组抗原的方法。

8. 发明申请

WO02009750A2 VACCINES FOR EQUINE HERPESVIRUS TYPE-1: VIRUSES HARBORING MUTATIONS WITHIN THE IMMEDIATE EARLY GENE 审中-公开
标题翻译： EQUINE HERPESVIRUS TYPE-1的疫苗：立即将来的基因中的病毒携带突变
公开(公告)号：WO02009750A2
公开(公告)日：2002-02-07
申请号：PCT/US2001/023612
申请日：2001-07-27
IPC分类号： G01N33/483 , A61K39/245 , A61K39/27 , A61P31/22 , C07K14/03 , C07K14/035 , C12N7/00 , C12N7/04 , C12N15/09 , C12Q1/68 , C12Q1/70 , G01N27/447 , G01N33/53 , G01N33/569 , A61K39/12
CPC分类号： C07K14/005 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/543 , C12N7/00 , C12N2710/16722 , C12N2710/16734 , C12N2710/16761
摘要： This invention relates to mutant Equine herpesvirus type-1 (EHV-1) isolates, and in particular, EHV-1 isolates carrying mutations in the immediate-early (IE) gene of the viral genome. A panel of EHV-1 mutant isolates have been described. Preffered EHV-1 isolates are those which are replication-competent and nonpathogenic. The mutant EHV-1 isolates of the present invention are useful in formulating vaccine compositions for preventing and treating EHV-1 infections in horses. The present invention further provides methods of determining the pathogenicity of an EHV-1 virus present in a horse subject which has been previously immunized with a non-pathogenic EHV-1 isolate of the present invention.
摘要翻译：本发明涉及突变型马疱疹病毒1型（EHV-1）分离株，尤其涉及在病毒基因组的即时早期（IE）基因中携带突变的EHV-1分离物。已经描述了一组EHV-1突变体分离物。优先的EHV-1分离株是具有复制能力和非致病性的分离株。本发明的突变体EHV-1分离物可用于配制用于预防和治疗马中的EHV-1感染的疫苗组合物。本发明还提供了确定已经用本发明的非致病性EHV-1分离物预先免疫的马对象中存在的EHV-1病毒的致病性的方法。

9. 发明申请

WO01066568A2 USE OF RECOMBINANT ANTIGENS TO DETERMINE THE IMMUNE STATUS OF AN ANIMAL 审中-公开
标题翻译：使用重组抗原来确定动物的免疫状态
公开(公告)号：WO01066568A2
公开(公告)日：2001-09-13
申请号：PCT/US2001/007251
申请日：2001-03-07
IPC分类号： C07K14/005 , C07K14/015 , C07K14/03 , C07K14/08 , C07K14/13 , C07K14/15 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/02 , G01N33/53 , G01N33/536 , G01N33/569
CPC分类号： C07K14/005 , C12N2710/16722 , C12N2740/13022 , C12N2750/14322 , C12N2750/14343 , C12N2760/18422 , G01N33/56983
摘要： The present invention includes a method to determine the immune status of an animal that includes the steps of (a) contacting a biological specimen of the animal with a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent, under conditions suitable for formation of a complex between the recombinant antigen and the antibody and (b) detecting the presence or absence of the complex, wherein presence or absence of a complex is indicative of the immune status of the animal. Preferably such a method indicates whether the animal should be vaccinated. The present invention also includes an assay comprising (a) a recombinant infectious agent antigen that is specific for detecting an antibody selective for that infectious agent; and (b) a means to detect an antibody that selectively binds to the recombinant antigen. Also included in the present invention are recombinant antigens and nucleic acid molecules encoding such antigens as well as methods to produce and use such nucleic acid molecule and recombinant antigens.
摘要翻译：本发明包括确定动物的免疫状态的方法，其包括以下步骤：（a）在条件下使动物的生物标本与特异于检测针对该感染因子的抗体的重组感染原体抗原接触适合于在重组抗原和抗体之间形成复合物，和（b）检测复合物的存在或不存在，其中复合物的存在或不存在指示动物的免疫状态。优选地，这种方法指示动物是否应该接种疫苗。本发明还包括一种测定法，其包含（a）特异于检测针对该感染因子的抗体的抗体的重组感染原体抗原; 和（b）检测选择性结合重组抗原的抗体的方法。本发明还包括编码这种抗原的重组抗原和核酸分子以及产生和使用这种核酸分子和重组抗原的方法。

10. 发明申请

WO1997049825A1 CANINE HERPESVIRUS BASED RECOMBINANT LIVE VACCINE, IN PARTICULAR AGAINST CANINE DISTEMPER, RABIES OR THE PARAINFLUENZA 2 VIRUS 审中-公开
标题翻译：基于犬类基于蛋白酶的重组生物疫苗，特别是针对犬类疾病，RABIES或PARAINFLUENZA 2病毒
公开(公告)号：WO1997049825A1
公开(公告)日：1997-12-31
申请号：PCT/FR1997001115
申请日：1997-06-23
申请人： MERIAL , AUDONNET, Jean-Christophe , BAUDU, Philippe
发明人： MERIAL
IPC分类号： C12N15/86
CPC分类号： C12N15/86 , A61K39/00 , C07K14/005 , C12N2710/16722 , C12N2710/16743 , C12N2760/18422 , C12N2760/20122
摘要： The recombinant live vaccine comprises, as a vector, a herpesvirus vaccine comprising and expressing at least one nucleotide sequence coding for the polypeptide, this sequence being inserted in a site not essential for replication, in particular among the group consisting of COL3, COL5, the thymidine kinase gene, the sequence located between the COL CHV orf19 and the COL CHV orf22, by simple insertion, or after total or partial deletion.
摘要翻译：重组活疫苗包含作为载体的疱疹病毒疫苗，其包含并表达至少一个编码多肽的核苷酸序列，该序列插入不必要复制的位点，特别是在COL3，COL5，胸苷激酶基因，位于COL CHV orf19和COL CHV orf22之间的序列，通过简单插入，或在全部或部分缺失后。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式